(Press-News.org) An implant that releases the medication dexamethasone within the eye appears safe and effective for the treatment of some types of uveitis (swelling and inflammation in the eye's middle layer), according to a report posted online today that will appear in the May print issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
"Uveitis refers to a group of intraocular inflammatory diseases that cause 10 percent to 15 percent of blindness in the developed world," the authors write as background information in the article. "Despite advances in immunosuppressive treatments, corticosteroids remain the mainstay of therapy." However, some patients cannot tolerate or do not respond to systemic corticosteroids, in part because the medications do not cross the blood-retinal barrier. Eye drops containing corticosteroids are effective only for anterior uveitis, closer to the front of the eye. Injections of corticosteroids directly into the eye have been effective in forms of intermediate or posterior uveitis, but require repeated treatments every two to three months and are associated with cataracts and other adverse effects.
To address these issues, an intravitreal (within the vitreous fluid of the eye), bioerodible, sustained-release implant has been developed to deliver a glucocorticoid medication, dexamethasone, to the back of the eye chamber. Careen Lowder, M.D., Ph.D., of the Cleveland Clinic Cole Eye Institute, and colleagues in the Ozurdex HURON Study Group conducted a 26-week randomized controlled trial involving 229 patients with intermediate or posterior uveitis. A total of 77 patients received an implant with a 0.7-milligram dose of dexamethasone, 76 received an implant with a 0.35-milligram dose and 76 underwent a sham procedure which followed the same protocol but used a needleless applicator.
After eight weeks, the eyes were evaluated for the presence and degree of vitreous haze, or inflammation that obscures visualization. Vitreous haze was scored from zero to four, with zero indicating no inflammation and four indicating the most severe inflammation, obscuring the optic nerve. At the beginning of treatment, participants had an average vitreous haze score of two.
At the eight-week follow-up, a vitreous haze score of zero was observed in 47 percent of eyes with the 0.7-milligram implant, 36 percent of those with the 0.35-milligram implant and 12 percent of those who underwent the sham procedure. There was no significant difference between the two treatment doses, and the benefit associated with the implant persisted through the 26-week study.
In addition, the percentage of eyes that achieved at least a 15-letter improvement in visual acuity was two- to six-fold greater in both implant groups than in the control group throughout the study.
"Typically, the most common adverse events associated with intravitreal corticosteroids, which may have impacted use in the past, including increases in intraocular pressure [pressure within the eye] and cataract. On any given follow-up visit in the present study, substantial increases in intraocular pressure (to 25 millimeters of mercury or greater) occurred in less than 10 percent of treated eyes," the authors write. In addition, only one of 62 phakic (with lenses) eyes required surgery to remove a cataract.
"In conclusion, the present study demonstrated that in patients with non-infectious intermediate or posterior uveitis, a single dose of the dexamethasone intravitreal implant was well tolerated and produced significant improvements in intraocular inflammation and visual acuity that persisted for six months," the authors conclude. "Overall, the 0.7-milligram dexamethasone intravitreal implant demonstrated greater efficacy than the 0.35-milligram dexamethasone intravitreal implant, with similar safety."
###
(Arch Ophthalmol. Published online January 10, 2011. doi:10.1001/archophthalmol.2010.339. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This study was sponsored by Allergan, Inc., which participated in the design of the study, data analysis and interpretation and supervised the preparation of the manuscript and approved the final version. Co-authors Dr. Robinson, Dr. Schiffman, Dr. Li, Dr. Cui and Dr. Whitcup are employees of Allergan Inc. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact Careen Lowder, M.D., Ph.D., call Maureen Nagg at 216-444-5703 or e-mail naggm@ccf.org.
For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.
END
Bottle rockets can cause significant eye injuries in children, often leading to permanent loss of vision, according to a report posted online today that will appear in the May print issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Of the estimated 9,200 emergency department admissions resulting from fireworks-related injuries each year, about 1,400 cases involve the eyes, according to background information in the article. A disproportionate number of these injuries are caused by bottle rockets. Bottle rockets are about half the size of a normal ...
Although the 2009 H1N1 influenza pandemic infected an estimated 60 million people and hospitalized more than 250,000 in the United States, it also brought one significant benefit—clues about how to make a vaccine that could protect against multiple strains of influenza.
In the Jan. 10, 2011, issue of the Journal of Experimental Medicine, researchers from the University of Chicago and Emory University report that people who were infected with pandemic H1N1 and recovered had an extraordinary immune response, producing antibodies that are protective against a variety of ...
All secondary school students should be required to be trained in cardiopulmonary resuscitation (CPR) and receive an overview of automated external defibrillators (AEDs), according to an American Heart Association science advisory.
The advisory, published in Circulation: Journal of the American Heart Association, calls for state legislatures to mandate that CPR and AED training be required for graduation, and to provide funding and other support to ensure the educational standard is met.
Last school year, 36 states had a law or curriculum standard encouraging CPR training ...
If you smoke around your children, they could have high blood pressure or be headed in an unhealthy direction before learning their ABC's, according to research reported in Circulation: Journal of the American Heart Association.
The study is the first to show that breathing tobacco smoke increases the blood pressure of children as young as 4 or 5 years old.
"The prevention of adult diseases like stroke or heart attack begins during childhood," said Giacomo D. Simonetti, M.D., first author of the study at the University of Heidelberg in Germany and currently assistant ...
Teenagers who consume a lot of added sugars in soft drinks and foods may have poor cholesterol profiles — which may possibly lead to heart disease in adulthood, according to first-of-its-kind research reported in Circulation: Journal of the American Heart Association.
"Added sugars" are any caloric sweeteners added to foods or beverages by the manufacturer during processing or the consumer.
The National Health and Nutrition Survey (NHANES) of 2,157 teenagers (ages 12 to 18) found the average daily consumption of added sugars was 119 grams (28.3 tsp or 476 calories), ...
According to an Emory University study, teenagers with high sugar diets may be in store for heart problems as adults.
A study published in the Jan. 10 online issue of the journal Circulation finds teens who consume elevated amounts of added sugars in drinks and foods are more likely to have poor cholesterol and triglyceride profiles now which may lead to heart disease later in life.
The study also finds that overweight or obese teens with the highest levels of added sugar intake had increased signs of insulin resistance, often a precursor to diabetes.
According to ...
Melt off from small mountain glaciers and ice caps will contribute about 12 centimetres to world sea-level increases by 2100, according to UBC research published this week in Nature Geoscience.
The largest contributors to projected global sea-level increases are glaciers in Arctic Canada, Alaska and landmass bound glaciers in the Antarctic. Glaciers in the European Alps, New Zealand, the Caucasus, Western Canada and the Western United Sates--though small absolute contributors to global sea-level increases--are projected to lose more than 50 per cent of their current ice ...
A Spanish study has challenged the long-held belief that people in the Mediterranean all enjoy more healthy diets and lifestyles, after discovering alarmingly high cardiovascular risk factors similar to those found in the UK and USA.
Research published in the January issue of IJCP, the International Journal of Clinical Practice, also found strong links between low levels of education and increased risk.
"Cardiovascular diseases account for 33 per cent of deaths in Spain, making it the main cause of mortality in the country" says Dr Ricardo Gómez-Huelgas from the Internal ...
A strange, glowing green cloud of gas that has mystified astronomers since its discovery in 2007 has been studied by Hubble. The cloud of gas is lit up by the bright light of a nearby quasar, and shows signs of ongoing star formation.
One of the strangest space objects ever seen is being scrutinised by the penetrating vision of the NASA/ESA Hubble Space Telescope. A mysterious, glowing green blob of gas is floating in space near a spiral galaxy. Hubble uncovered delicate filaments of gas and a pocket of young star clusters in the giant object, which is the size of the ...
Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.
Led by the University of Leicester, scientists from the University of Lisbon (led by Dr Tiago Outeiro) and University of California at San Francisco (led by Dr Paul Muchowski) collaborated to generate novel approaches for tackling the diseases. Their work, funded by the Medical Research Council, is published in The Journal of Biological Chemistry.
At Leicester, ...
